Horizon Discovery Group PLC (HZD) Given Consensus Rating of “Buy” by Analysts
Shares of Horizon Discovery Group PLC (LON:HZD) have been assigned a consensus recommendation of “Buy” from the six research firms that are currently covering the firm, MarketBeat Ratings reports. Two research analysts have rated the stock with a hold rating and three have issued a buy rating on the company. The average 1-year price target among analysts that have covered the stock in the last year is GBX 240 ($3.25).
HZD has been the topic of several research analyst reports. Numis Securities reiterated a “buy” rating and issued a GBX 300 ($4.07) price objective on shares of Horizon Discovery Group in a research note on Thursday, September 21st. N+1 Singer upped their price objective on Horizon Discovery Group from GBX 219 ($2.97) to GBX 250 ($3.39) and gave the company a “buy” rating in a research note on Friday, September 22nd.
Horizon Discovery Group (HZD) opened at GBX 215 ($2.92) on Thursday. Horizon Discovery Group has a 12 month low of GBX 160 ($2.17) and a 12 month high of GBX 294 ($3.99). The firm has a market capitalization of $320.54 and a P/E ratio of -1,535.71.
COPYRIGHT VIOLATION NOTICE: “Horizon Discovery Group PLC (HZD) Given Consensus Rating of “Buy” by Analysts” was first posted by American Banking News and is owned by of American Banking News. If you are viewing this article on another website, it was copied illegally and reposted in violation of United States and international copyright laws. The correct version of this article can be accessed at https://www.americanbankingnews.com/2018/01/11/horizon-discovery-group-plc-hzd-given-consensus-rating-of-buy-by-analysts.html.
About Horizon Discovery Group
Horizon Discovery Group plc is a United Kingdom-based life science company. The Company uses gene editing and gene modulation application. Through the application of these technologies the Company enables researchers to alter almost any gene or modulate its function in human or mammalian cells to generate models that mimic the genetic abnormalities found in diseases such as cancer.
Receive News & Ratings for Horizon Discovery Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Discovery Group and related companies with MarketBeat.com's FREE daily email newsletter.